Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein.
Hogarty
Michael D
MD
Division of Oncology, The Children's Hospital of Philadelphia, Department of Pediatrics, The University of Pennsylvania School of Medicine, Colket Translational Research Building, Room 3020, 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA. hogartym@email.chop.edu
D006801:Humans; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D025521:Tumor Suppressor Proteins; D025801:Ubiquitin / Q000378:metabolism; D043222:Ubiquitin Thiolesterase / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism
D064549:Myeloid Cell Leukemia Sequence 1 Protein; D019253:Proto-Oncogene Proteins c-bcl-2; D025521:Tumor Suppressor Proteins; C506234:USP9X protein, human; D025801:Ubiquitin; C502830:HUWE1 protein, human; D044767:Ubiquitin-Protein Ligases; D043222:Ubiquitin Thiolesterase